Financial Performance - Net profit attributable to shareholders rose by 109.26% to CNY 32,778,005.79 for the first quarter of 2024, up from CNY 15,663,965.30 in the same period last year[4] - Operating revenue increased by 18.94% to CNY 186,435,635.64 in Q1 2024, compared to CNY 156,752,643.83 in Q1 2023[4] - Operating profit for Q1 2024 was CNY 38,397,100.78, compared to CNY 19,641,476.15 in Q1 2023, indicating a significant increase of about 95.7%[30] - Total comprehensive income for Q1 2024 was ¥31,985,083.04, compared to ¥14,877,653.90 in Q1 2023, an increase of 114.19%[32] - Basic earnings per share for Q1 2024 was CNY 0.28, compared to CNY 0.13 in Q1 2023, reflecting an increase of about 115.4%[30] Assets and Liabilities - Total assets increased by 15.35% to CNY 1,333,373,579.79 as of March 31, 2024, compared to CNY 1,155,899,812.76 at the end of 2023[4] - The company's net asset attributable to shareholders increased by 30.76% to CNY 890,656,065.88 compared to CNY 681,132,245.85 at the end of 2023[4] - Total liabilities decreased to CNY 442,717,513.91 from CNY 474,767,566.91, a reduction of approximately 6.8%[25] - Long-term borrowings rose to CNY 78,900,000.00 from CNY 31,700,000.00, indicating an increase of approximately 148.5%[25] - The debt-to-asset ratio decreased to 33.20% from 41.07%, indicating improved financial stability[4] Cash Flow - Cash flow from operating activities decreased by 49.71% to CNY 23,971,035.95, primarily due to the offset of pre-receivable accounts[7] - The company reported a significant increase in cash flow from financing activities, totaling CNY 211,625,250.08, attributed to funds raised from the initial public offering[7] - The net cash increase for the period was CNY 203,983,328.55, compared to CNY 25,681,531.90 in Q1 2023, indicating a substantial improvement[36] - Cash outflow from operating activities was CNY 106,997,519.28, down from CNY 128,475,301.79 in Q1 2023, reflecting improved cost management[35] Research and Development - Research and development expenses surged by 187.45% to CNY 13,859,412.24, reflecting increased investment in new products and technologies[6] - Research and development expenses in Q1 2024 amounted to CNY 13,859,412.24, significantly higher than CNY 4,821,478.03 in Q1 2023, marking an increase of about 187.5%[29] Shareholder Information - The total number of unrestricted shares increased from 56,425,340 to 57,079,807, representing a change of 1.16%[9] - The total number of restricted shares rose from 61,824,660 to 81,170,193, marking an increase of 31.36%[9] - The largest shareholder, Yu Shunji, holds 29,942,900 shares, accounting for 21.66% of the total shares[10] - The company has implemented an employee stock ownership plan, which has been approved by the shareholders' meeting[12] Legal Matters - The company faced three lawsuits related to trade secret infringement, with a total amount involved of 8,000,000 yuan, all of which have been resolved[13] - The company reached a settlement with Chengdu Guangming Optoelectronics Co., Ltd., agreeing to pay a settlement amount of RMB 30 million, which will not result in substantial financial loss due to commitments from the actual controller[14] Future Plans - The company plans to continue expanding its market presence and investing in R&D for new technologies and products[2]
戈碧迦(835438) - 2024 Q1 - 季度财报